Crimean-Congo Hemorrhagic Fever Virus – An Overview
Crimean-Congo haemorrhagic fever (CCHF) is a severe, life-threatening viral disease with a widespread global distribution, making it the most geographically extensive of the viral hemorrhagic fevers. Caused by the Crimean-Congo Hemorrhagic Fever Virus (CCHFV), this illness poses a serious threat to public health due to its high case fatality ratio, typically ranging from 10% to 40%, and its potential to cause epidemics and hospital-acquired outbreaks. The virus belongs to the genus *Orthonairovirus* in the family *Nairoviridae* and the order *Bunyavirales*. Its genome is composed of three segmented, negative-sense RNA molecules, which are designated Large (L), Medium (M), and Small (S).
The disease was first identified in the Crimean Peninsula in 1944, where it was initially named Crimean haemorrhagic fever. Decades later, in 1969, the pathogen was recognized as being the same as the one responsible for an illness observed in the Congo Basin in 1956, leading to the combination of the two place names into the current designation. CCHF is now considered endemic across all of Africa, the Balkans, the Middle East, and Asia, generally occurring in countries south of the 50th parallel north, which corresponds to the geographical limit of its principal tick vector.
Transmission and Principal Vector
CCHF is primarily a zoonotic disease, and the virus is maintained in nature via a transmission cycle involving ticks and animals. The main vector and reservoir for CCHFV are hard ticks, particularly those of the genus *Hyalomma*. These ticks are capable of transovarial and transstadial transmission, meaning they can pass the virus to their offspring and from one developmental stage to the next, allowing them to remain infectious throughout their lives.
Transmission to humans occurs mainly through two routes. Firstly, through the bite of an infected hard tick, most commonly from the *Hyalomma* genus. Secondly, by direct contact with the blood, secretions, organs, or other bodily fluids of infected livestock, such as cattle, sheep, and goats, during and immediately after slaughter. These animals develop a condition called viremia—where the virus enters the bloodstream—for about a week without showing any signs of illness, allowing the tick-animal-tick cycle to continue unnoticed. People in close contact with livestock, such as farmers, animal breeders, slaughterhouse workers, and veterinarians, are consequently at a significantly higher risk of infection.
The virus can also spread from person-to-person through close contact with the blood or other body fluids of infected patients. This human-to-human transmission is often responsible for hospital-acquired (nosocomial) infections, which occur when medical equipment is improperly sterilized, needles are reused, or healthcare workers care for patients without adequate personal protective equipment (PPE). The risk of mortality can be even higher in these hospital-acquired cases.
Clinical Presentation, Signs, and Symptoms
The incubation period for CCHF is dependent on the mode of infection. Following a tick bite, symptoms typically appear after 1 to 3 days, with a maximum of 9 days. When infection occurs via contact with infected blood or tissues, the incubation period is usually 5 to 6 days, with a documented maximum of 13 days.
The onset of the disease is characteristically sudden and abrupt. Initial, non-specific febrile symptoms resemble a severe flu-like illness and include high fever, muscle ache (myalgia), severe headache, dizziness, backache, neck pain and stiffness, sore eyes, and photophobia (sensitivity to light). Early gastrointestinal symptoms are also common, such as nausea, vomiting (which can become hemorrhagic), diarrhea, abdominal pain, and a sore throat. Affected individuals may also experience sharp mood swings, agitation, and confusion.
The illness may progress rapidly into the hemorrhagic phase, usually around the fourth day. Agitation is often replaced by sleepiness, depression, and lassitude. Clinical signs include a petechial rash (small red spots caused by bleeding into the skin) on internal mucosal surfaces, like the palate, and on the skin. These petechiae can develop into larger bruises called ecchymoses, and more severe bleeding manifestations may arise, including severe nosebleeds (epistaxis), bleeding gums, and uncontrolled bleeding at injection sites. In severe cases, patients may develop rapid kidney deterioration, sudden liver failure (hepatitis), pulmonary failure, and multi-organ failure. Death, often due to circulatory shock, disseminated intravascular coagulation (DIC), or severe internal bleeding, typically occurs in the second week of illness. For patients who survive, improvement usually begins around the ninth or tenth day, though recovery can be slow, sometimes accompanied by temporary poor vision, hearing, or memory loss.
Diagnosis, Treatment, and Prevention Strategies
The timely and accurate diagnosis of CCHF is critical for patient management and preventing further spread. Diagnosis is primarily achieved through laboratory tests that detect either the virus or the patient’s immune response. During the acute phase of the infection, diagnostic methods include Real-Time Polymerase Chain Reaction (RT-PCR) to detect the viral RNA. In later stages, Enzyme-Linked Immunosorbent Assay (ELISA) is used to detect IgM and IgG antibodies in the blood. Other methods like antigen detection and virus isolation are also available, though virus isolation requires specialized biosafety conditions.
There is currently no specific cure or widely approved vaccine for CCHF. Treatment is centered on early intensive supportive care to manage symptoms and complications. This care includes rigorous attention to fluid and electrolyte balance, oxygen supply, managing blood pressure, and addressing any secondary infections. The antiviral drug Ribavirin is the only medication often used, and while some clinical studies suggest a potential benefit, especially when administered within 48 hours of symptom onset, its overall efficacy in treating CCHF remains inconclusive and debated among researchers.
Given the lack of a widely available vaccine, prevention is the only effective measure to reduce infection rates. Prevention strategies focus on minimizing exposure to the tick vector and infected animals. This involves wearing protective clothing, using tick repellents (like DEET), and performing regular tick checks on oneself and pets in endemic areas. For occupational risks, workers in the livestock and meat processing industries must wear protective gear when handling animals or their tissues. Healthcare workers are advised to observe strict universal precautions, including the proper use of PPE and stringent infection control practices, to prevent human-to-human transmission in clinical settings. Public awareness campaigns remain the cornerstone of CCHF control in endemic regions, educating people about risk factors and protective measures.